Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech & Pharma.T.A, -- Ignore unavailable to you. Want to Upgrade?

To: Jibacoa who wrote (813)	2/11/2008 1:11:47 PM
From: Jibacoa	Read Replies (1) \| Respond to of 3722

DSCO is now up 15.8% after it received an "upgrade" to buy from hold with a target of $5.<g> Volume is already > 2M, which is > 2x its ADV bigcharts.marketwatch.com The analyst said that the FDA is likely satisfied with DSCO's application for Surfaxin for respiratory distress syndrome in premature infants. In Apr 2006, the FDA asked the company for more information on the drug in order to consider it for approval. The FDA accepted additional information in November and established a target date of May 1 to complete the review. DSCO has been in contact with the members of the FDA throughout the review process,& the risk of problems at the next evaluation & plant inspection seems low. DSCO is scheduled to report its 4thQ results on Thursday & the EL for the Q is $0.02 > in the 2006 4th Q.<g> If DSCO can achieve the $5 target ir woul be a 100% gain from present levels.<g> bigcharts.marketwatch.com Bernard